Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Influenza

  • Chapter
  • First Online:
The Clinician’s Vaccine Safety Resource Guide

  • 971 Accesses

Abstract

All persons without contraindications who are 6 months of age and older should receive annual vaccination with influenza vaccine. Inactivated influenza vaccine (abbreviation: IIV) is recommended for all age groups and during pregnancy. Live attenuated influenza vaccine (abbreviation: LAIV; trade name: FluMist®) is also an option for non-pregnant persons between 2 and 49 years of age (as recommended by the ACIP at the February 2018 meeting). Influenza vaccine should be given as soon as it becomes available (usually between August and October in the U.S.) in order to ensure the highest possible level of protection before rates of transmission increase. Peak transmission season is usually between December and March in the United States. Children less than 9 years of age receiving IIV for the first time ever should receive two doses at least one month apart; otherwise, one dose per year is sufficient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grohskopf, L.A., et al., Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018–19 Influenza Season. MMWR Recomm Rep, 2018. 67(3): p. 1–20.

    Google Scholar 

  2. Grohskopf, L.A., et al., Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018–19 Influenza Season. MMWR Morb Mortal Wkly Rep, 2018. 67(22): p. 643–5.

    Article  Google Scholar 

  3. Epidemiology and Prevention of Vaccine-Preventable Diseases, Hamborsky J, Kroger A, Wolfe S, eds. 2015, Centers for Disease Control and Prevention: Washington D.C.

    Google Scholar 

  4. Fry, A.M., et al., Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis, 2014. 14(2): p. 109–18.

    Article  CAS  Google Scholar 

  5. Tamma, P.D., M.C. Steinhoff, and S.B. Omer, Influenza infection and vaccination in pregnant women. Expert Rev Respir Med, 2010. 4(3): p. 321–8.

    Article  Google Scholar 

  6. Kostova, D., et al., Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011. PLoS One, 2013. 8(6): p. e66312.

    Article  CAS  Google Scholar 

  7. Centers for Disease Control and Prevention. People at High Risk of Developing Flu–Related Complications. 2018 [cited 2018 March]; Available from: https://www.cdc.gov/flu/about/disease/high_risk.htm.

  8. Shang, M., et al., Influenza-Associated Pediatric Deaths in the United States, 2010–2016. Pediatrics, 2018.

    Google Scholar 

  9. Estimates of deaths associated with seasonal influenza --- United States, 1976–2007. MMWR Morb Mortal Wkly Rep, 2010. 59(33): p. 1057–62.

    Google Scholar 

  10. Thompson, W.W., et al., Influenza-associated hospitalizations in the United States. JAMA, 2004. 292(11): p. 1333–40.

    Article  CAS  Google Scholar 

  11. Garten, R., et al., Update: Influenza Activity in the United States During the 2017–18 Season and Composition of the 2018–19 Influenza Vaccine. MMWR Morb Mortal Wkly Rep, 2018. 67(22): p. 634–42.

    Google Scholar 

  12. Greenhawt, M.J., et al., Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Ann Allergy Asthma Immunol, 2012. 109(6): p. 426–30.

    Article  CAS  Google Scholar 

  13. Greenhawt, M., P.J. Turner, and J.M. Kelso, Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. Annals of Allergy, Asthma & Immunology. 120(1): p. 49–52.

    Google Scholar 

  14. American Academy of Allergy Asthma and Immunology. Egg Allergy and the Flu Vaccine. [cited 2018 March]; Available from: https://www.aaaai.org/conditions-and-treatments/library/allergy-library/egg-allergy-and-the-flu-vaccine.

  15. Dreskin, S.C., et al., International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J, 2016. 9(1): p. 32.

    Article  Google Scholar 

  16. Young, B., et al., Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies. J Infect Dis, 2018. 217(5): p. 731–41.

    Article  Google Scholar 

  17. Clements, M.L., et al., Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol, 1986. 23(1): p. 73–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Belshe, R.B., et al., Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med, 2007. 356(7): p. 685–96.

    Article  CAS  Google Scholar 

  19. Centers for Disease Control and Prevention. Vaccine Effectiveness - How Well Does the Flu Vaccine Work? 2017 [cited 2018 March]; Available from: https://www.cdc.gov/flu/about/qa/vaccineeffect.htm.

  20. Brady, R.C., et al., Randomized trial to compare the safety and immunogenicity of CSL Limited’s 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children. Vaccine, 2014. 32(52): p. 7141–7.

    Article  CAS  Google Scholar 

  21. Greenberg, D.P., et al., Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J, 2014. 33(6): p. 630–6.

    Article  Google Scholar 

  22. Baxter, R., et al., A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J, 2010. 29(10): p. 924–30.

    Article  Google Scholar 

  23. Nolan, T., et al., Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir Viruses, 2009. 3(6): p. 315–25.

    Article  CAS  Google Scholar 

  24. Domachowske, J.B., et al., A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis, 2013. 207(12): p. 1878–87.

    Article  CAS  Google Scholar 

  25. Langley, J.M., et al., Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis, 2013. 208(4): p. 544–53.

    Article  CAS  Google Scholar 

  26. Tregnaghi, M.W., et al., Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study. Viral Immunol, 2012. 25(3): p. 216–25.

    CAS  PubMed  Google Scholar 

  27. Beran, J., et al., Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis, 2013. 13: p. 224.

    Article  CAS  Google Scholar 

  28. Nicholson, K.G., et al., Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis, 2011. 11(2): p. 91–101.

    Article  CAS  Google Scholar 

  29. Salmon, D.A., et al., Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet, 2013. 381(9876): p. 1461–8.

    Article  Google Scholar 

  30. Vellozzi, C., S. Iqbal, and K. Broder, Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis, 2014. 58(8): p. 1149–55.

    Article  Google Scholar 

  31. Centers for Disease Control and Prevention. Misconceptions about Seasonal Flu and Flu Vaccines. 2017 [cited 2018 March]; Available from: https://www.cdc.gov/flu/about/qa/misconceptions.htm.

  32. Centers for Disease Control and Prevention, Vaccine Information Statement - Live Attenuated Influenza Vaccine. 2015.

    Google Scholar 

  33. Callaghan, W.M., A.A. Creanga, and D.J. Jamieson, Pregnancy-Related Mortality Resulting From Influenza in the United States During the 2009–2010 Pandemic. Obstet Gynecol, 2015. 126(3): p. 486–90.

    Article  Google Scholar 

  34. Zaman, K., et al., Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med, 2008. 359(15): p. 1555–64.

    Article  CAS  Google Scholar 

  35. Rasmussen, S.A., D.J. Jamieson, and T.M. Uyeki, Effects of influenza on pregnant women and infants. Am J Obstet Gynecol, 2012. 207(3 Suppl): p. S3–8.

    Article  Google Scholar 

  36. Phadke, V.K. and S.B. Omer, Maternal vaccination for the prevention of influenza: current status and hopes for the future. Expert Rev Vaccines, 2016. 15(10): p. 1255–80.

    Article  CAS  Google Scholar 

  37. Bratton, K.N., et al., Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis, 2015. 60(5): p. e11–9.

    Article  CAS  Google Scholar 

  38. Regan, A.K., et al., Seasonal Trivalent Influenza Vaccination During Pregnancy and the Incidence of Stillbirth: Population-Based Retrospective Cohort Study. Clin Infect Dis, 2016. 62(10): p. 1221–7.

    Article  Google Scholar 

  39. Fell, D.B., et al., Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG: An International Journal of Obstetrics & Gynaecology, 2015. 122(1): p. 17–26.

    Article  CAS  Google Scholar 

  40. Fell, D.B., et al., Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015. Vaccine, 2017. 35(18): p. 2279–87.

    Article  Google Scholar 

  41. Savitz, D.A., et al., Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. Vaccine, 2015. 33(47): p. 6430–5.

    Article  Google Scholar 

  42. Tamma, P.D., et al., Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol, 2009. 201(6): p. 547–52.

    Article  CAS  Google Scholar 

  43. Bednarczyk, R.A., D. Adjaye-Gbewonyo, and S.B. Omer, Safety of influenza immunization during pregnancy for the fetus and the neonate. Am J Obstet Gynecol, 2012. 207(3 Suppl): p. S38–46.

    Article  CAS  Google Scholar 

  44. Keller-Stanislawski, B., et al., Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine, 2014. 32(52): p. 7057–64.

    Article  CAS  Google Scholar 

  45. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec, 2012. 87(47): p. 461–76.

    Google Scholar 

  46. McMillan, M., et al., Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine, 2015. 33(18): p. 2108–17.

    Article  CAS  Google Scholar 

  47. Polyzos, K.A., et al., Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. Obstet Gynecol, 2015. 126(5): p. 1075–84.

    Article  CAS  Google Scholar 

  48. Kharbanda, E.O., et al., Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. Obstet Gynecol, 2013. 122(3): p. 659–67.

    Article  Google Scholar 

  49. Fabiani, M., et al., A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy. Vaccine, 2015. 33(19): p. 2240–7.

    Article  Google Scholar 

  50. Ludvigsson, J.F., et al., Risk for Congenital Malformation With H1N1 Influenza Vaccine: A Cohort Study With Sibling Analysis. Ann. Intern. Med, 2016. 165(12): p. 848–55.

    Article  Google Scholar 

  51. Sukumaran, L., et al., Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol, 2015. 126(5): p. 1069–74.

    Article  CAS  Google Scholar 

  52. Donahue, J.G., et al., Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. Vaccine, 2017. 35(40): p. 5314–22.

    Article  CAS  Google Scholar 

  53. Chambers, C.D., R. Xu, and A.A. Mitchell, Commentary on: “Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12”. Vaccine, 2017. 35(40): p. 5323–24.

    Article  CAS  Google Scholar 

  54. Steinhoff, M.C., et al., Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis, 2017. 17(9): p. 981–89.

    Article  Google Scholar 

  55. Chambers, C.D., et al., Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine, 2013. 31(44): p. 5026–32.

    Article  Google Scholar 

  56. Chambers, C.D., et al., Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine, 2016. 34(37): p. 4443–49.

    Article  CAS  Google Scholar 

  57. Chavant, F., et al., The PREGVAXGRIP Study: a Cohort Study to Assess Foetal and Neonatal Consequences of In Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza. Drug Safety, 2013. 36(6): p. 455–65.

    Article  CAS  Google Scholar 

  58. Huang, W.T., et al., Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan. Vaccine, 2014. 32(48): p. 6463–8.

    Article  CAS  Google Scholar 

  59. Ludvigsson, J.F., et al., Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. Bmj, 2015. 351: p. h5585.

    Article  Google Scholar 

  60. Ma, F., et al., Prospective cohort study of the safety of an influenza A(H1N1) vaccine in pregnant Chinese women. Clin Vaccine Immunol, 2014. 21(9): p. 1282–7.

    Article  CAS  Google Scholar 

  61. Oppermann, M., et al., A(H1N1)v2009: A controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine, 2012. 30(30): p. 4445–52.

    Article  Google Scholar 

  62. Pasternak, B., et al., Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ : British Medical Journal, 2012. 344.

    Article  Google Scholar 

  63. Tavares, F., et al., Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: A prospective cohort study. Vaccine, 2011. 29(37): p. 6358–65.

    Article  CAS  Google Scholar 

  64. Irving, S.A., et al., Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion. Obstetrics & Gynecology, 2013. 121(1): p. 159–65.

    Article  Google Scholar 

  65. Sammon, C.J., et al., Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. PLoS One, 2012. 7(12): p. e51734.

    Article  CAS  Google Scholar 

  66. Heikkinen, T., et al., Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol, 2012. 207(3): p. 177.e1–8.

    Article  Google Scholar 

  67. de Vries, L., et al., Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands. Birth Defects Res A Clin Mol Teratol, 2014. 100(10): p. 731–8.

    Article  CAS  Google Scholar 

  68. Bednarczyk, R.A., D. Adjaye-Gbewonyo, and S.B. Omer, Safety of influenza immunization during pregnancy for the fetus and the neonate. American Journal of Obstetrics & Gynecology, 2012. 207(3): p. S38–S46.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Epidemiologist, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Matthew Z. Dudley PhD, MSPH

  2. Professor, Departments of International Health and Health, Behavior and Society, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Daniel A. Salmon PhD, MPH

  3. Professor Emeritus, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Professor Emeritus, Department of Pediatrics, Johns Hopkins School of Medicine, Director Emeritus, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Neal A. Halsey MD

  4. Professor of Medicine, Pediatrics, Global Health, and Epidemiology, Emory University, Associate Director, Emory Vaccine Center, Director, Center of Excellence for Influenza Research and Surveillance (Emory-UGA CEIRS), Former President, National Foundation for Infectious Diseases (NFID), Atlanta, GA, USA

    Walter A. Orenstein MD, DSc (Hon)

  5. Associate Director for Behavioral Research, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Rupali J. Limaye PhD, MPH, MA

  6. Associate Professor, Pediatrics-Infectious Diseases, University of Colorado School of Medicine, Denver, CO, USA

    Sean T. O’Leary MD, MPH

  7. William H. Foege Professor of Global Health, Professor of Epidemiology and Pediatrics, Emory University, Atlanta, GA, USA

    Saad B. Omer MBBS, PhD, MPH

Authors
  1. Matthew Z. Dudley PhD, MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Salmon PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neal A. Halsey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter A. Orenstein MD, DSc (Hon)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rupali J. Limaye PhD, MPH, MA
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sean T. O’Leary MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Saad B. Omer MBBS, PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dudley, M.Z. et al. (2018). Influenza. In: The Clinician’s Vaccine Safety Resource Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-94694-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-94694-8_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-94693-1

  • Online ISBN: 978-3-319-94694-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation